SER SERINA THERAPEUTICS INC Capital Structure Changes 8-K Filing 2023 - Debt-Equity Swaps AgeX Therapeutics, Inc. has entered into an exchange agreement with Juvenescence Limited to issue 211,600 shares of Series A Preferred Stock and 148,400 shares of Series B Preferred Stock in exchange for cancellation of $36 Million of debt from outstanding loans. The exchange is intended to bring AgeX's common stock back into compliance with NYSE American's listing requirements. The agreement, however, is subject to NYSE's approval and is expected to be completed by July 25, 2023.Get access to all SEC 8-K filings of the SERINA THERAPEUTICS INC